

## SUPPLEMENTARY FIGURES

### **Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals**

Neelakshi R. Jog<sup>1</sup>, Kendra A. Young<sup>2</sup>, Melissa E. Munroe<sup>1</sup>, Michael T. Harmon<sup>1</sup>, Joel M. Guthridge<sup>1</sup>, Jennifer A. Kelly<sup>1</sup>, Diane L. Kamen<sup>3</sup>, Gary S. Gilkeson<sup>3</sup>, Michael H. Weisman<sup>4</sup>, David R. Karp<sup>5</sup>, Patrick M. Gaffney<sup>1</sup>, John B. Harley<sup>6,7,8</sup>, Daniel J. Wallace<sup>4</sup>, Jill M. Norris<sup>2</sup>, Judith A. James<sup>1,9</sup>

<sup>1</sup>Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

<sup>2</sup>Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

<sup>3</sup>Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA

<sup>4</sup>Division of Rheumatology, Cedar-Sinai Medical Center, Los Angeles, CA, USA

<sup>5</sup>Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA

<sup>6</sup>Center of Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA


<sup>7</sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

<sup>8</sup>US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA


<sup>9</sup>Departments of Medicine and Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

**Correspondence:** Judith A. James, MD, PhD, Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, 825 NE 13<sup>th</sup> Street, Oklahoma City, OK 73104, Phone: 405-271-4987, Fax: (405) 271-7063, Email: [judith-james@omrf.org](mailto:judith-james@omrf.org)

**Short title:** EBV sero-reactivation in lupus transition



**Figure S1. Relatives who subsequently transitioned to SLE had similar levels of total IgG as baseline compared to those who did not transition.** Total IgG levels in serum were measured by ELISA at the baseline visit. A. Total IgG levels in relatives who transitioned to SLE (Transition, n=55) and matched relatives who did not transition to SLE (Non-Transition, n=94). B. Relatives who did not transition were divided based on ANA positivity status into ANA+ (n=47) and ANA- (n=47). Data are represented as median  $\pm$  95% CI. \* $p < 0.05$  by Mann Whitney.



**Figure S2. Relatives who transitioned to classified SLE had similar levels of VZV IgG compared to relatives who did not transition and unrelated controls.** IgG responses towards Varicella zoster (VZV IgG) were measured by ELISA. A. VZV IgG levels at baseline in relatives who transitioned to SLE (Transition, n=55), matched relatives who did not transition to SLE (Non-Transition, n=94), and unaffected unrelated controls (Control n=47). B. into ANA+ (n=47) and ANA- (n=47). Data are represented as median  $\pm$  95% CI.  $p > 0.05$  by Mann-Whitney.